MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

49.68
-1.01
-1.99%
Closed 17:26 05/29 EDT
OPEN
51.01
PREV CLOSE
50.69
HIGH
51.32
LOW
48.00
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
53.70
52 WEEK LOW
21.56
MARKET CAP
7.74B
P/E (TTM)
-31.4809
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACAD stock price target is 59.27 with a high estimate of 74.00 and a low estimate of 41.00.

EPS

ACAD News

More
Now�s the Time to Buy These 3 Stocks
MotleyFool.com · 2d ago
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
Business Wire · 3d ago
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr.
Benzinga · 3d ago
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
Zacks · 4d ago
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $53
Oppenheimer maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $48 to $53.
Benzinga · 4d ago
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating pimavanserin for the adjunctive treatment
Business Wire · 5d ago
Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/21 22:48
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
Business Wire · 05/21 14:00

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About ACAD

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
More

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.